The suggested cut-off point in our study was higher than 0.2 ng/mL, which is the European Association of Urology (EAU) guideline for diagnosing biochemical recurrence in patients after a radical prostatectomy [14]; however, the [68Ga]Ga-PSMA-11 PET/CT study has recently become the most reliable imaging modality to allow confirmation or exclusion of PCa metastases and uses a cut-off point to distinguish patients, which might be helpful in qualifying them into appropriate treatment. Here, FOLH1 is linked to posterior cortical atrophy.